Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| PATH | OTHER |
| Institut Pasteur de Madagascar | OTHER |
| Université d'Antananarivo | UNKNOWN |
Not provided
Not provided
Not provided
The purpose of this study is to determine the health impacts of consistent consumption of insect-fortified crackers among school-aged children in Madagascar.
Specifically, in this RCT, the investigators will assess whether the insect-fortified crackers can improve the health status of Malagasy school children. The investigators' objectives are to: (1) Assess changes in gut microbiome composition that occur after 6 and 14 weeks of cracker consumption through 16S rRNA sequencing. (2) Assess changes in intestinal and systemic inflammation after 6 and 14 weeks of cracker consumption through quantification of fecal calprotectin, lactoferrin, myeloperoxidase (MPO), and alpha-1-antitrypsin (AAT) and circulating pro-inflammatory cytokines. (3) Assess changes in iron status after 14 weeks of cracker consumption through quantification of hemoglobin (Hb), inflammation-adjusted serum ferritin, and soluble transferrin receptor (sTfR).
Food insecurity, child malnutrition, and anemia remain significant public health problems globally, including in Madagascar where 40% of children under 5 years of age are chronically malnourished (stunted), 8% are wasted, and 46% are anemic (DHS, 2021). Interventions aimed at addressing this have often foundered on the fact that the foods that would address these nutrient deficiencies are physically unavailable, too expensive for poor households to purchase, or contribute to climate change or environmental degradation. Consequently, there is interest in the development of novel food products that could contribute to reducing malnutrition in all its forms, without the drawbacks of relying on existing food products. One possibility is to develop food products based on insects. Edible insects are low-cost, climate friendly, with nutritional profiles akin to meat. They contain high amounts of protein, iron, and zinc while also providing a novel source of prebiotic fiber. It is hypothesized that insect-based foods could improve children's health outcomes as measured by gut inflammation, anemia, and growth. The investigators and others have developed an insect-fortified cracker snack, suitable for the nutritional requirements of school-age children living in Southeast Madagascar. The investigators have already assessed the product's nutrient profile. They also have documented the safety tests done to date; these show that the snack is safe for human consumption. The test results have been submitted to the Malagasy regulatory authority for registering food and health products and the government has approved the insect powders as food for human consumption and issued "Certificates for Human Consumption". The investigators have also conducted an acceptability trial that showed that child participants like the organoleptic characteristics of the crackers and regularly consume the crackers in biologically meaningful quantities.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment | Experimental | Consumption of insect-fortified (crickets and black soldier fly larvae) crackers. |
|
| Control | Placebo Comparator | Consumption of rice and corn crackers |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cricket and Black Soldier Fly Larvae-fortified Cracker | Dietary Supplement | Children will receive a sachet containing 50g of insect crackers. 50 grams was chosen as the amount because the investigators know, from their earlier acceptability trial, that children are willing to consume this amount (in the acceptability trial, approximately 80% of children consumed 80% or more of the 50g of crackers that they were provided). Crackers will be provided Monday-Friday for approximately 14 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Gut mircrobiome | The investigators will assess gut microbiome composition at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through 16S rRNA sequencing and quantification of fecal biomarkers. | From enrollment to the end of treatment after 14 weeks of cracker consumption. |
| Iron via soluble transferrin receptor | The investigators will assess iron status at baseline (0 weeks) and endline (14 weeks) through soluble transferrin receptor (mg/L). | From enrollment to the end of treatment after 14 weeks of cracker consumption. |
| Intestinal inflammation via calprotectin | The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: calprotectin (µg/g). | From enrollment to the end of treatment after 14 weeks of cracker consumption. |
| Intestinal inflammation via lactoferrin | The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: lactoferrin (µg/g). | From enrollment to the end of treatment after 14 weeks of cracker consumption. |
| Intestinal inflammation via lipocalin | The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: lipocalin (ng/g). | From enrollment to the end of treatment after 14 weeks of cracker consumption. |
| Intestinal inflammation via anlpha-1 antitrypsin |
Not provided
Not provided
Inclusion criteria for children
Exclusion criteria for children
Inclusion criteria for parents • Willing to participate in completing surveys about demographics and household dynamics (assets, housing structure, etc.)
Exclusion criteria for parents
• Caregiver does not consent to participate
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| John Hoddinott, DPhil | Contact | 240-447-0918 | jfh246@cornell.edu | |
| Megan Parker, PhD | Contact | 202-460-6239 | mparker@path.org |
| Name | Affiliation | Role |
|---|---|---|
| John Hoddinott, DPhil | Cornell University | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| FSRP Sschools | Antsirabe | Vakinankaratra Region | Madagascar |
Not provided
July 2026 to July 2027
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Rice and Corn Cracker | Dietary Supplement | Children will receive a sachet containing 50g of insect crackers. 50 grams was chosen as the amount because the investigators know, from their earlier acceptability trial, that children are willing to consume this amount (in the acceptability trial, approximately 80% of children consumed 80% or more of the 50g of crackers that they were provided). Crackers will be provided Monday-Friday for approximately 14 weeks. |
|
|
The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: anlpha-1 antitrypsin (mg/g). |
| From enrollment to the end of treatment after 14 weeks of cracker consumption. |
| Intestinal inflammation via myeloperoxidase | The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: myeloperoxidase (µg/g). | From enrollment to the end of treatment after 14 weeks of cracker consumption. |
| Systemic inflammation via quantification of circulating cytokines | The investigators will also assess systemic inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through quantification of circulating cytokines, including IL-1β, IL-2, IL-4, IL-6, IL-10, IL-22, TNF-α, IFN-γ, CCL2, all expressed as pg/mL. | From enrollment to the end of treatment after 14 weeks of cracker consumption. |
| Iron via quantification of hemoglobin | The investigators will assess iron status at baseline (0 weeks) and endline (14 weeks) through quantification of hemoglobin (g/dL). | From enrollment to the end of treatment after 14 weeks of cracker consumption. |
| Iron via inflammation adjusted ferritin | The investigators will assess iron status at baseline (0 weeks) and endline (14 weeks) through inflammation adjusted ferritin (µg/L). | From enrollment to the end of treatment after 14 weeks of cracker consumption. |